ATE249824T1 - Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a - Google Patents

Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a

Info

Publication number
ATE249824T1
ATE249824T1 AT97926449T AT97926449T ATE249824T1 AT E249824 T1 ATE249824 T1 AT E249824T1 AT 97926449 T AT97926449 T AT 97926449T AT 97926449 T AT97926449 T AT 97926449T AT E249824 T1 ATE249824 T1 AT E249824T1
Authority
AT
Austria
Prior art keywords
mla
monophosphoryl lipid
type
hypersensitivity
treating hypersensitivity
Prior art date
Application number
AT97926449T
Other languages
German (de)
English (en)
Inventor
Jerry Dolovich
J Terry Ulrich
Jean S Marshall
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE249824T1 publication Critical patent/ATE249824T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT97926449T 1996-05-14 1997-05-08 Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a ATE249824T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/645,672 US5762943A (en) 1996-05-14 1996-05-14 Methods of treating type I hypersensitivity using monophosphoryl lipid A
PCT/US1997/007965 WO1997042947A1 (en) 1996-05-14 1997-05-08 Methods of treating type i hypersensitivity using monophosphoryl lipid a

Publications (1)

Publication Number Publication Date
ATE249824T1 true ATE249824T1 (de) 2003-10-15

Family

ID=24589990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97926449T ATE249824T1 (de) 1996-05-14 1997-05-08 Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a

Country Status (11)

Country Link
US (1) US5762943A (show.php)
EP (1) EP0914114B1 (show.php)
JP (1) JP4105230B2 (show.php)
AT (1) ATE249824T1 (show.php)
AU (1) AU3121497A (show.php)
CA (1) CA2252604C (show.php)
DE (1) DE69724970T2 (show.php)
DK (1) DK0914114T3 (show.php)
ES (1) ES2205231T3 (show.php)
PT (1) PT914114E (show.php)
WO (1) WO1997042947A1 (show.php)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4086928B2 (ja) * 1997-02-13 2008-05-14 大日本住友製薬株式会社 タイプ２ヘルパーｔ細胞型サイトカイン産生選択的抑制剤
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9724531D0 (en) * 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
ES2229745T3 (es) * 1998-07-14 2005-04-16 Wyeth Holdings Corporation Composicionde adyuvante y vacuna que contienen monofosforil lipido a.
EP1671646A3 (en) * 1998-09-18 2007-08-29 Dynavax Technologies Corporation Methods of treating IgE-associated disorders and compositions for use therein
AU766492B2 (en) * 1998-09-18 2003-10-16 Dynavax Technologies Corporation Methods of treating IgE-associated disorders and compositions for use therein
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
CA2767116A1 (en) * 1999-05-13 2000-11-23 Wyeth Holdings Corporation Adjuvant combination formulations
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
CA2409221C (en) * 2000-05-19 2010-10-26 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US20030105032A1 (en) * 2000-05-19 2003-06-05 Persing David H. Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
EE200300172A (et) * 2000-11-10 2003-06-16 Wyeth Holdings Corporation Antigeenne kompositsioon ja adjuvantsegu
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
RU2289410C2 (ru) * 2001-04-04 2006-12-20 Корикса Корпорейшн Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах
GB0120150D0 (en) * 2001-08-17 2001-10-10 Glaxosmithkline Biolog Sa Novel compounds
DE10359351A1 (de) * 2003-12-16 2005-07-21 Merck Patent Gmbh DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
WO2008153541A1 (en) 2006-09-26 2008-12-18 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2563390A4 (en) * 2010-04-30 2014-05-14 Allovate Llc METHOD AND ARTICLE FOR PREVENTING OR REDUCING THE RISK OF DEVELOPING A HYPERALGENIC IMMUNE SYSTEM
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN105960241A (zh) * 2014-01-21 2016-09-21 免疫设计公司 用于治疗过敏性病症的组合物
JP2016210771A (ja) * 2015-05-01 2016-12-15 日東電工株式会社 アレルギーワクチン組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058021A3 (en) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US5244663A (en) * 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
KR900701304A (ko) * 1988-05-05 1990-12-01 루이즈 츄이 콜린스 에이미 사람 및/또는 동물용 알레르겐 탈감작제
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
JP2838800B2 (ja) * 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
WO1993015766A1 (en) * 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens

Also Published As

Publication number Publication date
DE69724970T2 (de) 2004-07-22
PT914114E (pt) 2004-02-27
WO1997042947A1 (en) 1997-11-20
EP0914114A1 (en) 1999-05-12
JP2000510844A (ja) 2000-08-22
JP4105230B2 (ja) 2008-06-25
AU3121497A (en) 1997-12-05
EP0914114B1 (en) 2003-09-17
DE69724970D1 (de) 2003-10-23
ES2205231T3 (es) 2004-05-01
DK0914114T3 (da) 2003-10-20
CA2252604C (en) 2009-09-08
CA2252604A1 (en) 1997-11-20
US5762943A (en) 1998-06-09

Similar Documents

Publication Publication Date Title
ATE249824T1 (de) Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
FI972431A7 (fi) Sytotoksisten T-lymfosyyttivasteiden induktio
MX9800684A (es) Formulacion de proteinas liofilizadas isotonicas estables.
EE04239B1 (et) Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine
ATE34078T1 (de) Arzneiform zur oralen verabreichung sowie verfahren zu deren herstellung durch gefriertrocknen einer oel-in-wasser-emulsion.
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
DE69836268D1 (de) Immunverstärkende Zusammensetzung in fester Verabreichungsform mit Kollagen oder Polydimethylsiloxan als Trägersubstanzen
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
DE69428295D1 (de) Perkutane Behandlung mit Mastzelldegranulatoren zur Behandlung von Reizstoffüberempfindlichkeit
DE69530308D1 (de) Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung
BR9507846A (pt) Composição farmacéutica estável e fortemente concentrada de principio ativo da classe dos taxóides escolhido entre o docetaxol ou os derivados do docetaxol processo de preparação desta composição e utilização de uma solução congelada ou liofilizada
DE69635496D1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
Shalit et al. Challenge of mast cells with increasing amounts of antigen induces desensitization
NO933261L (no) Blanding til forsterkning av immunforsvaret
DK0744957T3 (da) Præparat og fremgangsmåde til forebyggelse og behandling af inflammation med immunoglobulin A
DE69330752D1 (de) Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii-spezifische mhc allopeptide
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
Vischer Mitogenic factors produced by lymphocyte activation: effect on T-and B-cells
Dhalla et al. Calcium binding and ATPase activities of heart sarcolemma
Hartmann INDUCTION OF A HEMOLYSIN RESPONSE IN VITRO: II. Influence of the Thymus-Derived Cells During the Development of the Antibody-Producing Cells
FI956028A0 (fi) Estreenisteroidit ihmisen hypotalaamisen toiminnan muuttamisen neurokemiallisina initiaattoreina sekä tähän liittyvät farmaseuttiset koostumukset ja menetelmät
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
KR20010043224A (ko) 백신 조성물

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0914114

Country of ref document: EP